The Swedish-British manufacturer AstraZeneca has indeed developed Evusheld, a combined preparation to prevent Covid-19 in adults. The first results of the tests have shown that the medicine – which consists of the active substances Tixagevimab and Cilgavimab – can be used effectively to protect against the disease. Experts are reviewing all the scientific data as well as the tests and are going to weigh the pros and cons of the drug. However, it is not yet clear when they will send their final assessment.
According to the EMA, AstraZeneca has not yet applied for authorization for the European market. So far, only the drug Remdesivir has been approved in the European Union as a special drug against the coronavirus. However, approval procedures for five other treatments are still ongoing.